- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Abeona secures cash runway with $155m priority review voucher sale | ||
| Di | GLP-1RAs show anti-cancer benefits beyond weight loss | ||
| Di | MHRA approves AstraZeneca's Trixeo Aerosphere inhaler for COPD | ||
| Mo | Roche plans $700m manufacturing plant in the US | ||
| Mo | Novo Nordisk's Sogroya matches Norditropin in children's growth disorders | ||
| Mo | Minghui and Qilu Pharmaceutical to advance MHB088C in Greater China | ||
| Mo | The advantages of isolator lines for large-scale pharma manufacturing | ||
| Mo | Trump to sign order tying US drug prices to global rates | ||
| Mo | LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment | ||
| Mo | Valneva's chikungunya vaccine use halted in older adults amid safety concerns | ||
| Mo | Lilly-Purdue partnership to invest $250m in pharma innovation | ||
| Mo | American Academy of Neurology (AAN) Annual Meeting 2025 | ||
| Fr | 5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends | ||
| Fr | HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines | ||
| Fr | Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales | ||
| Fr | NewBiologix licenses cell line technology to Recipharm Advanced Bio | ||
| Fr | FDA chief Martin Makary sets June deadline for genAI rollout | ||
| Fr | Haya secures $65m in Series A funds to advance heart failure treatment | ||
| 08.05. | Viralgen and Trogenix to progress gene therapy for glioblastoma | ||
| 08.05. | VC firm Vivo Capital outlays $740m for biotech investment | ||
| 08.05. | BioVaxys and Sona partner to develop cancer therapeutics | ||
| 08.05. | ARS Pharma's epinephrine nasal spray 1mg now available in US | ||
| 07.05. | European biotechs must understand US culture while seeking funding | ||
| 07.05. | FDA grants RMAT status to Opus Genetics' OPGx-LCA5 gene therapy | ||
| 07.05. | Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .